Initial experience with HydroPearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids
Open Access
- 31 March 2021
- journal article
- research article
- Published by Springer Nature in CVIR Endovascular
- Vol. 4 (1) , 1-7
Abstract
Background: Uterine Artery Embolization (UAE) is a minimally invasive procedure used to treat symptomatic uterine fibroids. The HydroPearl Microsphere (Terumo Interventional Systems) is an embolic agent approved for UAE and other embolization procedures. The purpose of this article is to describe our initial experience with HydroPearl for UAE in patients with symptomatic uterine fibroids. Twenty-one patients who underwent UAE using HydroPearl Microspheres at a single institution from May 1, 2018 to December 31, 2019 were included in the study. The electronic medical record (EMR) was reviewed for documentation of short- and long-term complications, as well as improvements in menorrhagia and bulk-type symptoms. We also describe unique attributes of the HydroPearl Microsphere that should be considered when utilizing this embolization particle for UAE. Results: Of the 21 patients, 18 had a 3-month or later post-procedure follow-up documented in the EMR and were included in the analysis. The average time between the UAE procedure and the most recent clinical note was 145 days. Sixteen patients reported symptoms of menorrhagia and 13 reported bulk symptoms prior to the UAE procedure. On follow-up, 13/16 patients (81%) and 12/13 patients (92%) experienced improvement in menorrhagia and bulk symptoms, respectively. The only recorded complication was amenorrhea in 4 patients (22%) who had an average age of 51 years. Conclusions: Several characteristics of HydroPearl Microsphere may prove helpful when considering these embolic particles for use in UAE. Our initial experience with this embolic agent suggest that the reatment response for menorrhagia and bulk symptoms are largely similar to success rates reported in the literature for other embolic agents. Larger studies are needed to evaluate the safety and efficacy of this embolic particle for this indication.Keywords
Funding Information
- Terumo
This publication has 16 references indexed in Scilit:
- Endocrine Conditions in Older Adults: Menopause.2018
- Reintervention risk and quality of life outcomes after uterine-sparing interventions for fibroids: a systematic review and meta-analysisFertility and Sterility, 2018
- Proposal of a New Adverse Event Classification by the Society of Interventional Radiology Standards of Practice CommitteeJournal of Vascular and Interventional Radiology, 2017
- Clinical Efficacy and Complications of Uterine Artery Embolization in Symptomatic Uterine FibroidsGlobal Journal of Health Science, 2015
- Intermediate and long-term outcomes following uterine artery fibroid embolizationEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2015
- Quality Improvement Guidelines for Uterine Artery Embolization for Symptomatic LeiomyomataJournal of Vascular and Interventional Radiology, 2014
- Uterine artery embolization versus surgery for symptomatic uterine fibroids: a randomized controlled trial and a meta-analysis of the literatureArchives of Gynecology and Obstetrics, 2011
- Uterine Artery Embolization for Treatment of LeiomyomataObstetrics & Gynecology, 2008
- Limited Uterine Artery Embolization for Leiomyomas with Tris-Acryl Gelatin Microspheres: 1-Year Follow-upJournal of Vascular and Interventional Radiology, 2006
- FEMIC (Fibromes Embolis s aux MICrosph res calibr es): Uterine Fibroid Embolization using Tris-acryl Microspheres. A French Multicenter StudyCardioVascular and Interventional Radiology, 2004